乳腺癌HER-2表达与临床病理相关性分析
|
摘要
目的:本文通过统计804例乳腺癌患者人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2),探讨乳腺癌Her-2表达与临床病理特征的相关性及临床意义。方法:收集1995年1月-2009年12月于我院进行治疗,病理证实为原发性乳腺癌,Her-2资料完整的女性患者共804例。采用回顾性分析的方法,统计804例乳腺癌患Her-2的表达,应用秩和检验及秩相关分析法,分析Her-2与多种相关因素,包括乳腺癌原发肿瘤的大小、淋巴结转移、病理分级、病理类型、分期、年龄、月经状态、雌激素受体ER、孕激素受体PR等临床病理特征相关性。结果:乳腺癌组织中Her-2表达在肿块大小、TNM分期分组间有统计学差异(P<0.05)。以上结果进一步行秩相关检验,得出乳腺癌肿块大小、TNM分期、预后均与Her-2表达呈正相关。Her-2表达在淋巴结转移数目、ER、PR不同有统计学差异(P<0.05)。但进一步行秩相关检验无明显相关性。Her-2表达不同年龄、月经状态、组织学分级与Her-2均无统计学差异(P>0.05)。Her-2表达不同无瘤及复发转移有统计学差异(P<0.05)。结论:Her-2基因表达在肿瘤大小、临床TNM分期、预后有关,通过Her-2检测能有效指导病情评估及判断预后。Her-2表达在不同ER、PR表达中无明显相关性,但Her-2过表达时ER、PR表达较弱。Her-2与ER、PR两者的联合检测有利于乳腺癌的治疗方案的选择。Her-2阳性表达、淋巴结无转移术后应给予加强辅助治疗。
Objective: In our experiment, the expression of Her-2 in breast cancer tissue of 804 cases were studied to analyze its correlation with tumor clinical pathology features and evaluate prognosis. Materials and methods: Collect the clinical data of 804 breast cancer cases who has treated in our hospital and final diagnosis is primary breast cancer by pathology result since 1995 to 2009. The correlation-ship of these three kinds of oncogenes with tumor biological behaviour such as the size, ER, PRl, ympho node metastasis、patho-histological type and rank, stage were studied in Kruskal Wallis test of statistics and analyzed in grade related data method. The correlation-ship among Her-2 was also studied in order to confirm correlation-ship of Her-2 with their clinical pathology features in identical breast cancer tissue.Result:Breast cancer specimens were positive for Her-2 ,which correlated with the factors such as TNM stage , prognosis and tumor size(P<0.05).norelated with hormone receptor status (ER、PR) patho-histological type and rank、lymphonodes metastasis、location、age、menstruate(P<0.05)。Conclusion: Breast cancer Her-2 expression correlated with the factors such as TNM stage,prognosis and tumor size,which can evaluate prognosis. Measurement of Her-2, ER and PR in the breast cancers can be used to guide clinical treatment.Her-2 positive expression、no lymphonodes metastasis patients should be intensive subsidiary treated.
Objective: In our experiment, the expression of Her-2 in breast cancer tissue of 804 cases were studied to analyze its correlation with tumor clinical pathology features and evaluate prognosis. Materials and methods: Collect the clinical data of 804 breast cancer cases who has treated in our hospital and final diagnosis is primary breast cancer by pathology result since 1995 to 2009. The correlation-ship of these three kinds of oncogenes with tumor biological behaviour such as the size, ER, PRl, ympho node metastasis、patho-histological type and rank, stage were studied in Kruskal Wallis test of statistics and analyzed in grade related data method. The correlation-ship among Her-2 was also studied in order to confirm correlation-ship of Her-2 with their clinical pathology features in identical breast cancer tissue.Result:Breast cancer specimens were positive for Her-2 ,which correlated with the factors such as TNM stage , prognosis and tumor size(P<0.05).norelated with hormone receptor status (ER、PR) patho-histological type and rank、lymphonodes metastasis、location、age、menstruate(P<0.05)。Conclusion: Breast cancer Her-2 expression correlated with the factors such as TNM stage,prognosis and tumor size,which can evaluate prognosis. Measurement of Her-2, ER and PR in the breast cancers can be used to guide clinical treatment.Her-2 positive expression、no lymphonodes metastasis patients should be intensive subsidiary treated.
引文
[1] Wang S,SaboorianMH, FrenkelEP,etal.Assessment ofHer-2 /neu status in breastcaneer.AutomatedCellularImagingSystem(ACIS)-assisted quantitation of immunohistoehemieal assay a-ehieves high accuracy in comparison with fluorescence in situ hy-bridization assay as the standard[J]. Am JClin Patho,l 2001,116(4): 495-503.
[2] Slamon DJ, Clark GM,Wong SG, et al .Human breast cancer:correlation of relapse and survival with amplification of the Her- 2/neu oncogene[J].Science, 1987, 235( 4785) : 177~182
[3] Sw iatoniow ski G,Dabrow skaM ,Klaniew ski T ,et al . Erb-overexpression in breast cancer[J].Ginekol Pol ,2003 ,74 (4) : 332-338.
[4] Gottf ried K, Giovanni P , Mark P , et al . Quantitative association between Her-2/ neu and steroid hormone receptors in hormone receptor positive primary breast cancer[J]. J Natl Cancer Ins ,2003 ,95 :142-153.
[5] Rao AV , Mohammed WA , Ragoonanan C , et al . Evaluation of est rogen and progesterone receptors , and cerbB-2 in carcinoma of t he breast in Trinidadian women[J]. West Indian Med J ,2002 ,51 (1) :4-9.
[6] Climent MA , Segui MA , Peiro G, et al . Prognostic value of Her-2/ neu and p53 expression in node-positive breast cancer .Her-2/ neu effect on adjuvant tamoxifen t reatment[J]. Breast , 2001 ,10 (1) :67-77.
[7] Quenel N , Wafflart J , Bonichon F , et al . The prognostic value of cerbB-2 in primary breast carcinomas:a study of 942 cases[J].Breast Cancer Res Treat ,1995 ,35 :283-291.
[8] Andrulis IL , Bull SB , Blackstein ME , et al . For t he Toronto Breast Cancer Study Group. Neu/ erbB-2 amplification identifies a poor-prognosis group of women wit h node-negative breast cancer[J]. J Clin Oncol ,1998 ,16 :1340-1349.
[9] Borg A , Baldertorp B , Ferno M , et al . ErbB-2 amplification in breast cancer wit h a high rate of proliferation[J].Oncogene ,1991 ,6 :137-143.
[10]藤晓东.癌基因C2erbB22在乳腺癌的表达及意义[J].中国临床与康复,1997, 4 (1):28-29.
[11]许良中.乳腺病理学[M] .上海:上海医科大学出版社,1999:110- 125.
[12]Gzzaniga P,Gradilone A,Giuliani L,et al.Expression and prognostic significance ofLivin,Survivin and other apoptosis related genes in the progression of superficial bladder cancer[J].Ann Oncol,2003,14(1):85-90.
[13]Swiatoniowski G,Dabrowska M ,Klaniewski T ,et al . Erb - 2overexpression in breast cancer[J]. Ginekol Pol ,2003 ,74 (4) : 332-338
[14]Biunno I, PozziMR, Pierotti MA,et a1.Structure and expression of oncogenes in surgical specimens of humanbreast carcinoma[J]. Br J Cancer, 1988; 57(5): 464-468
[15]Fontaine J,Tesseraux M,Klein V, et al. Gene amplification and expression of the neu (C-erbB-2) sequence in human mammary carcinoma. oncology[J] ,1988;45(5):360-363.
[16]Ross JS,Fletcher JA.Her-2/neu(c-erbB-2)gene and protein in breast cancer[J].Am J Clin Pathol.l999;112(1 suppll):553- 57.
[17]Taucher S, Rudas M, Mader RM, et a1.Do we need Her-2/neu testing for all patients with primary breast carcinoma? [J].Cancer,2003;98(12):2547-2553.
[18]Gennari R, Curigliano G, Rotmensz N, Breast carcinoma in elderly women:features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal[J]. Cancer. 2004;101(6):1302-I1310.
[19]张瑾等.乳腺癌Her-2过表达与内分泌状态对患者三苯氧胺治疗敏感性的观察.中华医学杂志[J], 2007; 87(46): 3268-3271.
[20]刘艳.乳腺癌Her-2基因过表达与年龄临床病理状态的相关性研究[J].中国肿瘤临床, 2007; 34(24): 1392-1395.
[21]陈舒婕.色素原位杂交法和免疫组织化学法检测乳腺癌Her-2基因扩增及蛋白表达[J].肿瘤, 2008; 28(8): 705-708.
[22]董筱莉.SSTR2与Her-2在乳腺癌组织中的表达及其临床意义[J].放射免疫学杂志, 2008; 21(5): 459-462.
[23]俞巍.荧光原位杂交法检测乳腺癌Her-2/neu表达及临床意义[J].首都医科大学学报, 2009; 30(1): 93-96.
[24]Radovic S,Babic M,Doric M,et al.Correlation of the Her-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer[J].Bosn J Basic Med Sci,2005;5(1):3-7.
[25]刘映.C-erbB-2, Ki67及GST:在乳腺癌中的表达及相互关系[J].中国现代医药杂志,2006, 6(8):9
[26]Allred DC,Clark GM, Tandon AK, et aI.Her-2/neu in node negative breast cancer:Prognostic significance of overexpression influenced by the presence of in situ carcinoma[J].J Clin Oncol,1992, 10(4):599-605
[27]Swede H,Moysich KB,Winston JS,et al.Variation of the prognostic significance of Her-2 expression in breast cancer according to tumorsize[J].Breast J, 2003;9(2):98-105.
[28]陈世荣等.Her-2和ER、PR在乳腺癌中的表达及其意义[J].苏州大学学报·医学版2007; 27(5): 745-747.
[29]陈舒婕.色素原位杂交法和免疫组织化学法检测乳腺癌Her-2基因扩增及蛋白表达[J].肿瘤, 2008; 28(8): 705-708.
[30]Disis ML, Schiffman K. Cancer vaccines targeting the Her-2/neu oncogenic protein [J]. Semin Oncol,2001,28:12- 20.
[31]Maru D, Middleton LP, Wang S,et al. Her-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger[J]. Cancer.2005;103(5):900-905.
[32]Pilch H, Weikel W, Kolbl H,et al, Long-term prognostic significance of Her-2/neu in untreated node-negative breast cancer depends on the method of testing[J]. Breast Cancer Res. 2005;7(2):256-266.
[33]Chearskul S, Onreabroi S, Churintrapun M,et al.Immunohistoche cal study of c-erbB-2 expression in primary breast cancer[J].Asian Pac J Allergy Immuno1, 2001;19(3):197-205.
[34]Horiguchi J, Iino Y, Takei Het al.C-erbB-2 status is an independent predictorof survival after first recurrence[J].lnt J Oncol. 1998;12(1):123-128.
[35]Zadrozny M, Smolarz B,Romanowicz M,et a1.Genetic analysis of Her-2/neu gene amplification in paraffin embedded tumor tissue in women with breast cancer[J]. Pol J Pathol, 2002,53(4):189-193.
[36]Zhou D, Dattifora H, et al. Association of Multiple Copies of the C-erbB-2 oncogene with Spead of Breast Cancer[J]. CancerRes, 1987,47(22):6123-612s.
[37]Quenel N, Wafflart J, Bonichon F, et a1.The prognostic value of c-erbB-2 in primary breast carcinomas: a study of 942 cases[J].Breast Cancer Res Treat,199s,3 s:283-291.
[38]Ariga R, Zarif A, Korasick J, et al. Correlation of Her-2/neu gene amplification with other pregnostic and predictive factors in female breast carcinoma[J]. Breast J, 200s,11(4):278-280.
[39]胡勇、饶慧蓉、吴强.癌基因C-erbB-2、抗癌基因P53在乳腺癌中表达的临床病理研究[J].临床与实验病理学杂志,1995;11 (1):6-10.
[40]张徽,米粟,李园园,等.癌基因蛋白C-erbB-2及PCNA在乳腺浸润性导管癌中的表达[J],诊断病理学杂志,1999;6(I): 32-33.
[41]詹熔洲、郑唯强、龚志锦等.乳腺肿瘤C-erbB-2表达及预后意义的研究[J].诊断病理学杂志[J],1994;(1):23-25.
[42]张学光.Her-2在乳腺癌组织中的表达及其与血管生成的关系[J].山东医药, 2008; 48(17): 82-83.
[43]刘莉娜.Her-2原癌基因和肿瘤微血管密度对乳腺癌预后判断的一致性研究[J].解放军医学杂志, 2008; 33(7): 865-867.
[44]李占文.176例Ⅱ、Ⅲ期乳腺癌腋淋巴结转移临床病理相关因素分析[J].临床外科杂志, 2005.05.20; 13(5): 282-284.
[45]Green S,Walter P,Kumar V,et al.Human oestrogen cDNA:sequence, expression and homology to verb-A[J].Nature,1986,320:134-139.
[46]Ray A, Sharma BK, Kaur S, et al, Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer[J].Indian J Exp Biol. 2004;42(3):253-258.
[47]Guo S, Sonenshein GE. Forkhead box transcription factor FOX03a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/ -phosphatidylinositol 3-kinase/Akt signaling pathway[J].Mol Cell Biol. 2004;24(19):8681-8690.
[48]Kolar Z,Murray PG,Zapletalova J.Expression of c-erbB-2 in node negativebreast cancer does not correlate with estrogen receptor status,predictors of hormone respoesiveness,or PCNA expression neoplasms[J],2002;49(2):110-113.
[49]Elledge RM,Green S,Ciocca D,et al.Her-2 expression and response to tamoxifen in estrogen positive breast cancer.A southwest oncology Group Study[J].Clin Cancer Research.1998,4(1):7-12.
[50]Jensen BV ,Johansen J S ,Price PA. High levels of serum Her22/ neu and YKL240 independently reflect aggressiveness of metastatic breast cancer[J].Clin Cancer Res ,2003 ,9 (12) :442324434.
[51]Tsutsui S , Ohno S ,Murakami S ,et al. Prognostic value of c2erbB2 expression in breast cancer[J]. Surg Oncol ,2002 ,79 (4) :2162223.
[52]王深明.乳腺癌血行转移与血管生成相关因子相关性研究[J].中华实验外科杂志, 2005.05.08; 22(5): 524-526.
[53]车艺,历红元. P53、C-erbB-2在乳腺癌中的表达及其预后价值[J] .重庆医学, 2003, 32( 1) : 57- 59.
[54]麦国丰,罗荣城,马树东,等. Her-2表达与乳腺癌预后的相关性研究[J] .解放军医学杂志, 2003, 28( 10) : 902-903.
[55]张丽,徐毅,梅国华. Bcl-2, Bax二种基因在乳腺癌中的关系[J] .中国冶金工业医学杂志, 2004, 21( 4) : 286-287.
[56]刘雪梅,黄剑飞. Bcl-2, Bax在乳腺癌中表达的临床意义[J] .河南肿瘤学杂志, 2005, 18( 1) : 14- 16.
[57]华彬,韦军民.乳癌Her-2基因研究的进展与现状[J] .中国医刊, 2006, 41( 1) : 46- 48.
[1] Strauss B. Best hope or last hope access to phaseⅢclini2 cal trials of Her22 /neu for advanced stage breast cancer patients[J]. J Adv Nurs, 2000, 31: 259-266.
[2] Reese DM , Slamon DJ . Her - 2 neu signal t ransduction in human breast and ovarian cancer[J]. Stemcells ,1997 ,15 (1) :18
[3] Swiatoniowski G,Dabrowska M ,Klaniewski T ,et al . Erb - 2overexpression in breast cancer[J]. Ginekol Pol ,2003 ,74 (4) : 332-338
[4] Ross JS.Fletcher JA. The Her- 2/neu oncogene:prognostic factor,Predictive factor and target for therapy[J].Semin Cancer Biol, 1999, 9( 2) : 125-138
[5] Borwer ST, Ahmed S, Tartter PI, et al. Prognostic variables in invasivebreast cancer:Contribution of comedo versus noncomedo in situ component[J].Ann Surg Oncol, 1995, 2( 5) : 440-444.
[6] De Potter CR, Schelfhout AM, Verbeeck P, et al. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast[J].Hum Pathol, 1995, 26( 6) : 601~606
[7] Azaclehstark, S,Hulka. S J.Her- 2/neu amplification in benign breast disease and the risk of subsequent breast cancer[J]. J Clinl Oncol, 2000, 18( 2) :267-284
[8] Tovey S,Dunne B, Witton GJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer[J]. Clin Cancer Res,2005, 11(12): 4835- 4842.
[9] Martin LA, Farmer I, Johnston SR, et al. Enhanced estrogenreceptor (ER) alpha, ERbB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7cells to long term estrogen deprivation[J]. J Biol Chem,2003, 278(33):30458- 30468.
[10]Gago FE, Fanelli MA, Ciocca DR, et al. Co-expression ofsteroid hormone receptors (estrogen receptorαand/or progesterone receptors)and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy[J]. J Steroid Biochem Mol Biol, 2006, 98(1):36-40.
[11]Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysison the interaction between Her-2 expression and response to endocrine treatment in advanced breast cancer[J]. Clin Cancer Res, 2005, 11(3): 4741- 4748.
[12]Pritchard KI, Shepherd LE, O’Malley FP, et al. Her2 and responsiveness of breast cancer to adjuvant chemotherapy[J]. N Engl J Med, 2006, 354(201):2103- 2111.
[13]Iish I,Harada M, Azuma K, et al. Her2/neu-derived peptides recognized by both cellular and humoral immunesystems in HLA2A2+cancer patients[J]. Int J Oncol, 2004,24(4): 9672- 9751.
[14]Lu J, Tan M, Huang WC, etal. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance[J].Clin Cancer Res, 2009,15(4):1326-1334.
[15]张新明潘琪Her - 2过表达乳腺癌患者术后的治疗进展[J].医学研究杂志2008,37 (12): 245- 255
[16]Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomeraseⅡa amplifications and deletions as predictive markers in primary breast cancer patientsrandomly assigned to cyclophosphamide, methotrexate,and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil[J]. Danish Breast Cancer Cooperative Group. J Clin Oncol, 2005, 23(30):7483- 7490.
[17]Luftner D, Jung A, Schmid P, et al. Upregulation of Her-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy innode-positive breast cancer patients[J]. Breast Cancer Res Treat, 2003, 80(3):245- 255.
[18]McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing[J].Her-2. Drugs, 2002, 62(1):209- 243.
[19]Papaldo P, Fabi A, Ferretti G, et al. PhaseⅡstudy onmetastatic breast cancer patients treated with weekly vinorelbinewith or without trastuzumab according to Her2expression: changing the natural history of Her2-positive disease[J]. Ann Oncol, 2006, 17(4):630- 636.
[20]Kirsch DG, Ledezma CJ, Mathews CS, et al. Brain metastases from breast cancer: survival by Her2 status in the trastuzumab era[J]. J Clin Oncol, 2004, 22(14 Suppl): 779.
[21]Le XF, Mao W, Lu C, Thornton A,etal. Specific blockade of VEGF and Her2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress Her-2[J].Cell Cycle. 2008,7(23):3747-3258.
[22]Kim IY, Yong HY, Kang KW,etal. Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9[J]. Cancer Lett,2009, 275(2):227-233.
[23]Lin NU, Diéras V, Paul D, Lossignol D,etal. Multicenter phase II study of lapatinib in patients with brain metastases from Her2-positive breast cancer[J]. Clin Cancer Res,2009, 15(4):1452-1459
[24]Jukkola A, Bloigu R, Soini Y, et al.C- erbB- 2 positivity is a factor for poorprognosis in breast cancer and poor response to hormonal orChemotherapy disease[J].Eur J Cancer, 2001, 37( 3) : 347-354.
[25]Linderholm B ,Andersson J ,Lindh B ,et al . Overexpression ofcerbB - 2 is related to a higher expression of vascular endo2t helial growt h factor and constitutes an independent prognos2tic factor in primary node - positive breast cancer after adju2vant systemic t reatment[J]. Eur J Cancer ,2004 ,40 (1) :33 -42.
[2] Slamon DJ, Clark GM,Wong SG, et al .Human breast cancer:correlation of relapse and survival with amplification of the Her- 2/neu oncogene[J].Science, 1987, 235( 4785) : 177~182
[3] Sw iatoniow ski G,Dabrow skaM ,Klaniew ski T ,et al . Erb-overexpression in breast cancer[J].Ginekol Pol ,2003 ,74 (4) : 332-338.
[4] Gottf ried K, Giovanni P , Mark P , et al . Quantitative association between Her-2/ neu and steroid hormone receptors in hormone receptor positive primary breast cancer[J]. J Natl Cancer Ins ,2003 ,95 :142-153.
[5] Rao AV , Mohammed WA , Ragoonanan C , et al . Evaluation of est rogen and progesterone receptors , and cerbB-2 in carcinoma of t he breast in Trinidadian women[J]. West Indian Med J ,2002 ,51 (1) :4-9.
[6] Climent MA , Segui MA , Peiro G, et al . Prognostic value of Her-2/ neu and p53 expression in node-positive breast cancer .Her-2/ neu effect on adjuvant tamoxifen t reatment[J]. Breast , 2001 ,10 (1) :67-77.
[7] Quenel N , Wafflart J , Bonichon F , et al . The prognostic value of cerbB-2 in primary breast carcinomas:a study of 942 cases[J].Breast Cancer Res Treat ,1995 ,35 :283-291.
[8] Andrulis IL , Bull SB , Blackstein ME , et al . For t he Toronto Breast Cancer Study Group. Neu/ erbB-2 amplification identifies a poor-prognosis group of women wit h node-negative breast cancer[J]. J Clin Oncol ,1998 ,16 :1340-1349.
[9] Borg A , Baldertorp B , Ferno M , et al . ErbB-2 amplification in breast cancer wit h a high rate of proliferation[J].Oncogene ,1991 ,6 :137-143.
[10]藤晓东.癌基因C2erbB22在乳腺癌的表达及意义[J].中国临床与康复,1997, 4 (1):28-29.
[11]许良中.乳腺病理学[M] .上海:上海医科大学出版社,1999:110- 125.
[12]Gzzaniga P,Gradilone A,Giuliani L,et al.Expression and prognostic significance ofLivin,Survivin and other apoptosis related genes in the progression of superficial bladder cancer[J].Ann Oncol,2003,14(1):85-90.
[13]Swiatoniowski G,Dabrowska M ,Klaniewski T ,et al . Erb - 2overexpression in breast cancer[J]. Ginekol Pol ,2003 ,74 (4) : 332-338
[14]Biunno I, PozziMR, Pierotti MA,et a1.Structure and expression of oncogenes in surgical specimens of humanbreast carcinoma[J]. Br J Cancer, 1988; 57(5): 464-468
[15]Fontaine J,Tesseraux M,Klein V, et al. Gene amplification and expression of the neu (C-erbB-2) sequence in human mammary carcinoma. oncology[J] ,1988;45(5):360-363.
[16]Ross JS,Fletcher JA.Her-2/neu(c-erbB-2)gene and protein in breast cancer[J].Am J Clin Pathol.l999;112(1 suppll):553- 57.
[17]Taucher S, Rudas M, Mader RM, et a1.Do we need Her-2/neu testing for all patients with primary breast carcinoma? [J].Cancer,2003;98(12):2547-2553.
[18]Gennari R, Curigliano G, Rotmensz N, Breast carcinoma in elderly women:features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal[J]. Cancer. 2004;101(6):1302-I1310.
[19]张瑾等.乳腺癌Her-2过表达与内分泌状态对患者三苯氧胺治疗敏感性的观察.中华医学杂志[J], 2007; 87(46): 3268-3271.
[20]刘艳.乳腺癌Her-2基因过表达与年龄临床病理状态的相关性研究[J].中国肿瘤临床, 2007; 34(24): 1392-1395.
[21]陈舒婕.色素原位杂交法和免疫组织化学法检测乳腺癌Her-2基因扩增及蛋白表达[J].肿瘤, 2008; 28(8): 705-708.
[22]董筱莉.SSTR2与Her-2在乳腺癌组织中的表达及其临床意义[J].放射免疫学杂志, 2008; 21(5): 459-462.
[23]俞巍.荧光原位杂交法检测乳腺癌Her-2/neu表达及临床意义[J].首都医科大学学报, 2009; 30(1): 93-96.
[24]Radovic S,Babic M,Doric M,et al.Correlation of the Her-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer[J].Bosn J Basic Med Sci,2005;5(1):3-7.
[25]刘映.C-erbB-2, Ki67及GST:在乳腺癌中的表达及相互关系[J].中国现代医药杂志,2006, 6(8):9
[26]Allred DC,Clark GM, Tandon AK, et aI.Her-2/neu in node negative breast cancer:Prognostic significance of overexpression influenced by the presence of in situ carcinoma[J].J Clin Oncol,1992, 10(4):599-605
[27]Swede H,Moysich KB,Winston JS,et al.Variation of the prognostic significance of Her-2 expression in breast cancer according to tumorsize[J].Breast J, 2003;9(2):98-105.
[28]陈世荣等.Her-2和ER、PR在乳腺癌中的表达及其意义[J].苏州大学学报·医学版2007; 27(5): 745-747.
[29]陈舒婕.色素原位杂交法和免疫组织化学法检测乳腺癌Her-2基因扩增及蛋白表达[J].肿瘤, 2008; 28(8): 705-708.
[30]Disis ML, Schiffman K. Cancer vaccines targeting the Her-2/neu oncogenic protein [J]. Semin Oncol,2001,28:12- 20.
[31]Maru D, Middleton LP, Wang S,et al. Her-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger[J]. Cancer.2005;103(5):900-905.
[32]Pilch H, Weikel W, Kolbl H,et al, Long-term prognostic significance of Her-2/neu in untreated node-negative breast cancer depends on the method of testing[J]. Breast Cancer Res. 2005;7(2):256-266.
[33]Chearskul S, Onreabroi S, Churintrapun M,et al.Immunohistoche cal study of c-erbB-2 expression in primary breast cancer[J].Asian Pac J Allergy Immuno1, 2001;19(3):197-205.
[34]Horiguchi J, Iino Y, Takei Het al.C-erbB-2 status is an independent predictorof survival after first recurrence[J].lnt J Oncol. 1998;12(1):123-128.
[35]Zadrozny M, Smolarz B,Romanowicz M,et a1.Genetic analysis of Her-2/neu gene amplification in paraffin embedded tumor tissue in women with breast cancer[J]. Pol J Pathol, 2002,53(4):189-193.
[36]Zhou D, Dattifora H, et al. Association of Multiple Copies of the C-erbB-2 oncogene with Spead of Breast Cancer[J]. CancerRes, 1987,47(22):6123-612s.
[37]Quenel N, Wafflart J, Bonichon F, et a1.The prognostic value of c-erbB-2 in primary breast carcinomas: a study of 942 cases[J].Breast Cancer Res Treat,199s,3 s:283-291.
[38]Ariga R, Zarif A, Korasick J, et al. Correlation of Her-2/neu gene amplification with other pregnostic and predictive factors in female breast carcinoma[J]. Breast J, 200s,11(4):278-280.
[39]胡勇、饶慧蓉、吴强.癌基因C-erbB-2、抗癌基因P53在乳腺癌中表达的临床病理研究[J].临床与实验病理学杂志,1995;11 (1):6-10.
[40]张徽,米粟,李园园,等.癌基因蛋白C-erbB-2及PCNA在乳腺浸润性导管癌中的表达[J],诊断病理学杂志,1999;6(I): 32-33.
[41]詹熔洲、郑唯强、龚志锦等.乳腺肿瘤C-erbB-2表达及预后意义的研究[J].诊断病理学杂志[J],1994;(1):23-25.
[42]张学光.Her-2在乳腺癌组织中的表达及其与血管生成的关系[J].山东医药, 2008; 48(17): 82-83.
[43]刘莉娜.Her-2原癌基因和肿瘤微血管密度对乳腺癌预后判断的一致性研究[J].解放军医学杂志, 2008; 33(7): 865-867.
[44]李占文.176例Ⅱ、Ⅲ期乳腺癌腋淋巴结转移临床病理相关因素分析[J].临床外科杂志, 2005.05.20; 13(5): 282-284.
[45]Green S,Walter P,Kumar V,et al.Human oestrogen cDNA:sequence, expression and homology to verb-A[J].Nature,1986,320:134-139.
[46]Ray A, Sharma BK, Kaur S, et al, Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer[J].Indian J Exp Biol. 2004;42(3):253-258.
[47]Guo S, Sonenshein GE. Forkhead box transcription factor FOX03a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/ -phosphatidylinositol 3-kinase/Akt signaling pathway[J].Mol Cell Biol. 2004;24(19):8681-8690.
[48]Kolar Z,Murray PG,Zapletalova J.Expression of c-erbB-2 in node negativebreast cancer does not correlate with estrogen receptor status,predictors of hormone respoesiveness,or PCNA expression neoplasms[J],2002;49(2):110-113.
[49]Elledge RM,Green S,Ciocca D,et al.Her-2 expression and response to tamoxifen in estrogen positive breast cancer.A southwest oncology Group Study[J].Clin Cancer Research.1998,4(1):7-12.
[50]Jensen BV ,Johansen J S ,Price PA. High levels of serum Her22/ neu and YKL240 independently reflect aggressiveness of metastatic breast cancer[J].Clin Cancer Res ,2003 ,9 (12) :442324434.
[51]Tsutsui S , Ohno S ,Murakami S ,et al. Prognostic value of c2erbB2 expression in breast cancer[J]. Surg Oncol ,2002 ,79 (4) :2162223.
[52]王深明.乳腺癌血行转移与血管生成相关因子相关性研究[J].中华实验外科杂志, 2005.05.08; 22(5): 524-526.
[53]车艺,历红元. P53、C-erbB-2在乳腺癌中的表达及其预后价值[J] .重庆医学, 2003, 32( 1) : 57- 59.
[54]麦国丰,罗荣城,马树东,等. Her-2表达与乳腺癌预后的相关性研究[J] .解放军医学杂志, 2003, 28( 10) : 902-903.
[55]张丽,徐毅,梅国华. Bcl-2, Bax二种基因在乳腺癌中的关系[J] .中国冶金工业医学杂志, 2004, 21( 4) : 286-287.
[56]刘雪梅,黄剑飞. Bcl-2, Bax在乳腺癌中表达的临床意义[J] .河南肿瘤学杂志, 2005, 18( 1) : 14- 16.
[57]华彬,韦军民.乳癌Her-2基因研究的进展与现状[J] .中国医刊, 2006, 41( 1) : 46- 48.
[1] Strauss B. Best hope or last hope access to phaseⅢclini2 cal trials of Her22 /neu for advanced stage breast cancer patients[J]. J Adv Nurs, 2000, 31: 259-266.
[2] Reese DM , Slamon DJ . Her - 2 neu signal t ransduction in human breast and ovarian cancer[J]. Stemcells ,1997 ,15 (1) :18
[3] Swiatoniowski G,Dabrowska M ,Klaniewski T ,et al . Erb - 2overexpression in breast cancer[J]. Ginekol Pol ,2003 ,74 (4) : 332-338
[4] Ross JS.Fletcher JA. The Her- 2/neu oncogene:prognostic factor,Predictive factor and target for therapy[J].Semin Cancer Biol, 1999, 9( 2) : 125-138
[5] Borwer ST, Ahmed S, Tartter PI, et al. Prognostic variables in invasivebreast cancer:Contribution of comedo versus noncomedo in situ component[J].Ann Surg Oncol, 1995, 2( 5) : 440-444.
[6] De Potter CR, Schelfhout AM, Verbeeck P, et al. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast[J].Hum Pathol, 1995, 26( 6) : 601~606
[7] Azaclehstark, S,Hulka. S J.Her- 2/neu amplification in benign breast disease and the risk of subsequent breast cancer[J]. J Clinl Oncol, 2000, 18( 2) :267-284
[8] Tovey S,Dunne B, Witton GJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer[J]. Clin Cancer Res,2005, 11(12): 4835- 4842.
[9] Martin LA, Farmer I, Johnston SR, et al. Enhanced estrogenreceptor (ER) alpha, ERbB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7cells to long term estrogen deprivation[J]. J Biol Chem,2003, 278(33):30458- 30468.
[10]Gago FE, Fanelli MA, Ciocca DR, et al. Co-expression ofsteroid hormone receptors (estrogen receptorαand/or progesterone receptors)and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy[J]. J Steroid Biochem Mol Biol, 2006, 98(1):36-40.
[11]Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysison the interaction between Her-2 expression and response to endocrine treatment in advanced breast cancer[J]. Clin Cancer Res, 2005, 11(3): 4741- 4748.
[12]Pritchard KI, Shepherd LE, O’Malley FP, et al. Her2 and responsiveness of breast cancer to adjuvant chemotherapy[J]. N Engl J Med, 2006, 354(201):2103- 2111.
[13]Iish I,Harada M, Azuma K, et al. Her2/neu-derived peptides recognized by both cellular and humoral immunesystems in HLA2A2+cancer patients[J]. Int J Oncol, 2004,24(4): 9672- 9751.
[14]Lu J, Tan M, Huang WC, etal. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance[J].Clin Cancer Res, 2009,15(4):1326-1334.
[15]张新明潘琪Her - 2过表达乳腺癌患者术后的治疗进展[J].医学研究杂志2008,37 (12): 245- 255
[16]Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomeraseⅡa amplifications and deletions as predictive markers in primary breast cancer patientsrandomly assigned to cyclophosphamide, methotrexate,and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil[J]. Danish Breast Cancer Cooperative Group. J Clin Oncol, 2005, 23(30):7483- 7490.
[17]Luftner D, Jung A, Schmid P, et al. Upregulation of Her-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy innode-positive breast cancer patients[J]. Breast Cancer Res Treat, 2003, 80(3):245- 255.
[18]McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing[J].Her-2. Drugs, 2002, 62(1):209- 243.
[19]Papaldo P, Fabi A, Ferretti G, et al. PhaseⅡstudy onmetastatic breast cancer patients treated with weekly vinorelbinewith or without trastuzumab according to Her2expression: changing the natural history of Her2-positive disease[J]. Ann Oncol, 2006, 17(4):630- 636.
[20]Kirsch DG, Ledezma CJ, Mathews CS, et al. Brain metastases from breast cancer: survival by Her2 status in the trastuzumab era[J]. J Clin Oncol, 2004, 22(14 Suppl): 779.
[21]Le XF, Mao W, Lu C, Thornton A,etal. Specific blockade of VEGF and Her2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress Her-2[J].Cell Cycle. 2008,7(23):3747-3258.
[22]Kim IY, Yong HY, Kang KW,etal. Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9[J]. Cancer Lett,2009, 275(2):227-233.
[23]Lin NU, Diéras V, Paul D, Lossignol D,etal. Multicenter phase II study of lapatinib in patients with brain metastases from Her2-positive breast cancer[J]. Clin Cancer Res,2009, 15(4):1452-1459
[24]Jukkola A, Bloigu R, Soini Y, et al.C- erbB- 2 positivity is a factor for poorprognosis in breast cancer and poor response to hormonal orChemotherapy disease[J].Eur J Cancer, 2001, 37( 3) : 347-354.
[25]Linderholm B ,Andersson J ,Lindh B ,et al . Overexpression ofcerbB - 2 is related to a higher expression of vascular endo2t helial growt h factor and constitutes an independent prognos2tic factor in primary node - positive breast cancer after adju2vant systemic t reatment[J]. Eur J Cancer ,2004 ,40 (1) :33 -42.